Table 2 Disease specific characteristics of patients with Rheumatoid Arthritis
RA phenotype | Data expressed as | Patients with RA, n = 68 |
|---|---|---|
Disease duration, years | median (IQR) | 17.3 (10.7, 25.7) (range 5.4, 43.4) |
Early morning stiffness, mins | median (IQR) | 13 (0, 45) (n = 62) |
History of orthopaedic joint surgery | n (%) | 19 (29.7) |
Number of orthopaedic joint surgical episodes | n (%) | 9 (14.1) - 1 episode |
3 (4.7) - 2 episodes | ||
5 (7.8) - 3 episodes | ||
2 (3.1) - 4 episodes | ||
Current use of oral prednisolone | n (%) | 3 (4.7) |
Current use of csDMARD | n (%) | 52 (81.3) |
Number of csDMARDs currently taking | n (%) | 40 (62.5) taking 1 |
8 (12.5) taking 2 | ||
6 (9.4) taking 3 | ||
Number of previously tried csDMARDs | median (IQR) | 2 (1, 3) (range 0, 7) |
Current use of biological DMARD | n (%) | 43 (67.2) |
 Current TNFI users | 19 (29.7) | |
 Current rituximab users | 21 (32.8) | |
 Current tocilizumab users | 2 (3.1) | |
 Current abatacept user | 1 (1.6) | |
Number of treatment cycles in current RTX users | median (IQR) | 4 (3, 5.5) (range 2, 9) |
Number of previously tried biological DMARDs | median (IQR) | 0 (0, 1) |
Patient general health VAS | median (IQR) | 31 (16, 53) (n = 59) |
TJC28 | median (IQR) | 2 (0, 6) |
SJC28 | median (IQR) | 0 (0, 1) |
HAQ-DI | median (IQR) | 1.50 (0.53, 2.00) (n = 60) |
3-variable DAS28-CRP | median (IQR) | 2.38 (1.15, 3.25) |
Erosions on hands/feet x-ray | n (%) | 50/61 (82) |
CRP (mg/L) | median (IQR) | 0 (0, 8.3) |
ESR (mm/h) | median (IQR) | 14 (6, 28) (n = 59) |
RF positive (≥ 40 iu/ml) | n (%) | 44 (68.8) |
ACPA positive (≥ 10 U/ml) | n (%) | 50/63 (79.4) |